Article
Oncology
Peiwei Yang, Fan Yu, Zheng Yao, Xu Ding, Hanmei Xu, Juan Zhang
Summary: This study verified the potential application of chimeric antigen receptor-T cells (CAR-T cells) targeting CD24 in the treatment of triple negative breast cancer (TNBC). 24BBz showed antigen-specific activation and dose-dependent cytotoxicity against CD24-positive breast cancer cells in vitro. In TNBC xenograft models, 24BBz exhibited significant anti-tumor effect. CD24-specific CAR-T cells have potent anti-tumor activity and potential application value in TNBC treatment.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Hidekiyo Yamaki, Michihisa Kono, Risa Wakisaka, Hiroki Komatsuda, Takumi Kumai, Ryusuke Hayashi, Ryosuke Sato, Toshihiro Nagato, Takayuki Ohkuri, Akemi Kosaka, Kenzo Ohara, Kan Kishibe, Miki Takahara, Tatsuya Hayashi, Hiroya Kobayashi, Akihiro Katada
Summary: Brachyury is a transcription factor involved in mesoderm formation and differentiation, and its overexpression is associated with poor prognosis in many cancers. This study identified antigenic peptide segments derived from Brachyury that can induce tumor-reactive T cells. Combination therapy using PD-1/PD-L1 blockade and GEM enhances the tumor-reactivity of Brachyury-reactive T cells. These findings suggest that immunotherapy targeting Brachyury with peptide, GEM, and immune checkpoint blockade holds promise for the treatment of head and neck cancer.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Review
Chemistry, Multidisciplinary
Yunfei Yi, Mian Yu, Wen Li, Dunwan Zhu, Lin Mei, Meitong Ou
Summary: The development of therapeutic cancer vaccines using nanotechnology has great potential in improving the limitations of current immunotherapies. Nanoparticles enhance vaccine stability and antigen recognition through their small size, while surface modifications allow targeted delivery. Nanocarriers with adjuvant effect also improve vaccine efficacy. Additionally, nanoparticle-mediated chemotherapy and radiotherapy induce the release of tumor antigens, simulating anti-tumor immune responses. These vaccine-like nanomedicines can effectively eliminate tumors and prevent recurrence and metastasis. This article presents recent advancements in nanoparticle-based antigen delivery for in situ anti-tumor vaccination and discusses the remaining opportunities and challenges for clinical translation.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Oncology
Mary K. McKenna, Ada Ozcan, Daniel Brenner, Norihiro Watanabe, Maureen Legendre, Dafydd G. Thomas, Christopher Ashwood, Richard D. Cummings, Challice Bonifant, David M. Markovitz, Malcolm K. Brenner
Summary: Researchers have developed a novel chimeric antigen receptor (CAR) based on plant lectins, which can recognize abnormal sugar residues on malignant cells and associated stromal cells. The CAR showed promising antitumor effects in models of pancreatic ductal adenocarcinoma (PDAC).
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Jie Wang, Kaichen Zhou, Huihuang Zhu, Fukun Wei, Sai Ma, Yi Kan, Bingheng Li, Lijun Mao
Summary: Currently, common treatments for prostate cancer include surgery, radiation therapy, chemotherapy, and hormone therapy. However, patients often experience high recurrence rates and may develop castration-resistant prostate cancer. Tumor vaccines, which utilize tumor-specific antigens (TSA) and tumor-associated antigens (TAA), aim to activate a specific immune response against cancer cells in the body. Different types of prostate cancer vaccines, such as cellular vaccines, extracellular-based anti-tumor vaccines, polypeptide vaccines, and nucleic acid vaccines, have been developed with the advancement of tumor vaccine technology. This review provides a summary of the current status and progress in the development of prostate cancer vaccines.
Review
Immunology
Chaoying Hu, Jianyang Liu, Feiran Cheng, Yu Bai, Qunying Mao, Miao Xu, Zhenglun Liang
Summary: This review summarizes the research progress of amplifying mRNA vaccines and provides an outlook on their prospects and future directions in cancer treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Materials Science, Biomaterials
Nian Liu, Xiangyu Xiao, Ziqiang Zhang, Chun Mao, Mimi Wan, Jian Shen
Summary: Cancer vaccines are a promising therapeutic strategy in clinical oncology, stimulating antitumor immunity to fight against cancer. However, there are several challenges that hinder their broad clinical translation.
ACS BIOMATERIALS SCIENCE & ENGINEERING
(2023)
Article
Immunology
Takumi Kumai, Hidekiyo Yamaki, Michihisa Kono, Ryusuke Hayashi, Risa Wakisaka, Hiroki Komatsuda
Summary: The success of immune checkpoint blockade has demonstrated the potential of immune cells to attack tumors. However, the non-specific activation of immune cells limits the clinical benefit to less than 20% of patients. Peptide-based immunotherapy, by targeting tumor antigens, offers a promising approach to develop tumor-specific immune responses. Recent advancements have shown that peptides, with suitable adjuvants, can elicit robust antitumor responses in both mice and humans.
Article
Immunology
Takashi Imai
Summary: This study investigated the impact of single amino acid deletion in the target antigen of plasmid DNA vaccines on vaccine efficacy, with results showing that minor modifications could enhance the efficacy of DNA vaccines against tumors or infectious diseases.
Article
Medicine, Research & Experimental
Quanwei Zhou, Xuejun Yan, Hecheng Zhu, Zhaoqi Xin, Jin Zhao, Wenyue Shen, Wen Yin, Youwei Guo, Hongjuan Xu, Ming Zhao, Weidong Liu, Xingjun Jiang, Caiping Ren
Summary: The study identified potential tumor antigens, KDR, COL1A2, and SAMD9, for mRNA vaccine development against diffuse glioma and found that immunotherapy targeting these antigens is more suitable for patients with immune subtype Ims1. The results provide insights into immunotherapy for diffuse glioma.
Review
Cell Biology
Roshni Saravanan, Vaishnavi Balasubramanian, Srikanth Swamy Swaroop Balamurugan, Inemai Ezhil, Zeba Afnaan, Jisha John, Sandhya Sundaram, Shanmugasundaram Gouthaman, Suresh B. Pakala, Suresh Kumar Rayala, Ganesh Venkatraman
Summary: Breast cancer, especially triple negative breast cancer (TNBC), is a major contributor to the global cancer burden. Zinc and zinc transporters play a crucial role in the prognosis and treatment of breast cancer. LIV1, a zinc transporter, has been identified as a key target for breast cancer prognosis and emerging treatment options. Early clinical trial results show that an antibody-drug conjugate targeting LIV1 can reduce tumor burden and induce immune responses, offering promise for TNBC patients.
JOURNAL OF CELLULAR PHYSIOLOGY
(2022)
Article
Immunology
Xin Zhang, Yanlong Zhang, Li Zhao, Jiayu Wang, Jiaxing Li, Xi Wang, Min Zhang, Xiaopeng Hu
Summary: This study identified potential tumor antigens for mRNA vaccines in bladder cancer (BLCA) and defined three immune subtypes in BLCA. It also applied the immcluster package to predict suitable BLCA patients for antitumor therapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Dandan Han, Fei Wang, Yichuan Ma, Yu Zhao, Wei Zhang, Ziyang Zhang, Huifang Liu, Xinjian Yang, Chi Zhang, Jinchao Zhang, Zhenhua Li
Summary: This study explores the use of engineered photosynthetic bacteria and outer membrane vesicles to enhance cancer immunotherapy. By capturing and transporting tumor antigens to the outer regions of the tumor, the researchers were able to promote efficient antigen presentation and trigger potent antitumor immune responses. This approach shows promising potential in the development of personalized cancer vaccination strategies.
Article
Chemistry, Multidisciplinary
Yiqun Du, Hongzhong Zhou, Ganglin Su, Mengdan Ma, Yuchen Liu
Summary: This study developed a protein corona-driven nanovaccine that effectively resists protein corona-induced antigen extracellular release and promotes antigen cytosolic release under reductive conditions. The nanovaccine demonstrated significant prophylactic and therapeutic antitumor response in a mouse model.
JOURNAL OF CONTROLLED RELEASE
(2022)
Article
Immunology
Nataliia Petruk, Arafat Siddiqui, Sina Tadayon, Jorma Maatta, Pieta K. Mattila, Arja Jukkola, Jouko Sandholm, Katri S. Selander
Summary: Bisphosphonates (BPs) are bone-protecting osteoclast inhibitors commonly used in the treatment of osteoporosis and skeletal complications of malignancies. In early breast cancer, adjuvant nitrogen-containing BPs have shown potential benefits, but there is a lack of biomarkers to predict response. This study investigates the mechanisms by which BPs exert their effects and identifies potential factors influencing their efficacy.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Food Science & Technology
Maria Laura De Marchis, Fiorella Guadagni, Erica Silvestris, Domenica Lovero, David Della-Morte, Patrizia Ferroni, Piero Barbanti, Raffaele Palmirotta
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
(2019)
Review
Oncology
Silvia Riondino, Patrizia Ferroni, Fabio Massimo Zanzotto, Mario Roselli, Fiorella Guadagni
Article
Oncology
Patrizia Ferroni, Fabio M. Zanzotto, Silvia Riondino, Noemi Scarpato, Fiorella Guadagni, Mario Roselli
Article
Oncology
Karin L. Lee, Stephen C. Benz, Kristin C. Hicks, Andrew Nguyen, Sofia R. Gameiro, Claudia Palena, John Z. Sanborn, Zhen Su, Peter Ordentlich, Lars Rohlin, John H. Lee, Shahrooz Rabizadeh, Patrick Soon-Shiong, Kayvan Niazi, Jeffrey Schlom, Duane H. Hamilton
CANCER IMMUNOLOGY RESEARCH
(2019)
Article
Oncology
Kristin C. Hicks, Karin M. Knudson, Karin L. Lee, Duane H. Hamilton, James W. Hodge, William D. Figg, Peter Ordentlich, Frank R. Jones, Shahrooz Rabizadeh, Patrick Soon-Shiong, Jeffrey Schlom, Sofia R. Gameiro
CLINICAL CANCER RESEARCH
(2020)
Review
Oncology
Silvia Riondino, Patrizia Ferroni, Girolamo Del Monte, Vincenzo Formica, Fiorella Guadagni, Mario Roselli
Review
Oncology
Karin L. Lee, Jeffrey Schlom, Duane H. Hamilton
Summary: Combining neoepitope vaccines with other cancer therapies may improve their clinical efficacies.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Review
Biochemistry & Molecular Biology
Cristina Morelli, Vincenzo Formica, Silvia Riondino, Antonio Russo, Patrizia Ferroni, Fiorella Guadagni, Mario Roselli
Summary: The study discusses the potential link between RAS, BRAF, and microsatellite instability with the efficacy of oxaliplatin and irinotecan in chemotherapy. KRAS mutation increases sensitivity to oxaliplatin, while limited data is available on the efficacy of BRAF mutations. Irinotecan shows enhanced cytotoxicity to MSI cell lines due to the involvement of mismatch repair components in DNA repair processes.
CURRENT MEDICINAL CHEMISTRY
(2021)
Article
Medicine, General & Internal
Vincenzo Formica, Jessica Lucchetti, Elena Doldo, Silvia Riondino, Cristina Morelli, Renato Argiro, Nicola Renzi, Daniele Nitti, Antonella Nardecchia, Emanuela Dell'Aquila, Patrizia Ferroni, Fiorella Guadagni, Giampiero Palmieri, Augusto Orlandi, Mario Roselli
Summary: This study demonstrates that mutational analysis through plasma can better predict survival outcomes for colorectal cancer patients, compared to relying solely on tumor tissue analysis. Plasma mutations further refine prognosis and can help guide clinical management.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Lucas A. Horn, Kristen Fousek, Duane H. Hamilton, James W. Hodge, John A. Zebala, Dean Y. Maeda, Jeffrey Schlom, Claudia Palena
Summary: Innovative strategies involving the addition of cancer vaccines to immune checkpoint blockade therapies can enhance antitumor efficacy by increasing the numbers of tumor-infiltrating T cells. These strategies have shown promising results in preclinical studies and may have potential in improving outcomes for patients resistant to current immunotherapies.
Review
Biochemistry & Molecular Biology
Antonio Jesus Banegas-Luna, Jorge Pena-Garcia, Adrian Iftene, Fiorella Guadagni, Patrizia Ferroni, Noemi Scarpato, Fabio Massimo Zanzotto, Andres Bueno-Crespo, Horacio Perez-Sanchez
Summary: Artificial intelligence has made astonishing progress in medicine, especially in cancer diagnosis and therapies. Machine learning models and in-silico tools are widely used, yet the interpretability of machine learning predictions for doctors is still an issue that needs improvement.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Editorial Material
Oncology
Patrizia Ferroni, Fiorella Guadagni, Mario Roselli
Article
Oncology
Hannah Reimann, Andrew Nguyen, J. Zachary Sanborn, Charles J. Vaske, Stephen C. Benz, Kayvan Niazi, Shahrooz Rabizadeh, Patricia Spilman, Andreas Mackensen, Matthias Ruebner, Alexander Hein, Matthias W. Beckmann, Edith D. van Der Meijden, Judith Bausenwein, Sascha Kretschmann, Marieke Griffioen, Jeffrey Schlom, James L. Gulley, Karin L. Lee, Duane H. Hamilton, Patrick Soon-Shiong, Peter A. Fasching, Anita N. Kremer
Summary: This study describes a program for identifying and validating neoepitopes and neoepitope-reactive T-cells to support the development of next-generation immunotherapies for BC patients. The program was validated using cell lines and tumor biopsies and demonstrated successful identification of tumor-specific immunogenic targets for individualized treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Oncology
Valentina Russo, Eleonora Lallo, Armelle Munnia, Miriana Spedicato, Luca Messerini, Romina D'Aurizio, Elia Giuseppe Ceroni, Giulia Brunelli, Antonio Galvano, Antonio Russo, Ida Landini, Stefania Nobili, Marcello Ceppi, Marco Bruzzone, Fabio Cianchi, Fabio Staderini, Mario Roselli, Silvia Riondino, Patrizia Ferroni, Fiorella Guadagni, Enrico Mini, Marco Peluso
Summary: Metastatic colorectal cancer (mCRC) has a high incidence and mortality rate. Innovative biomarkers have been developed for predicting treatment response. By analyzing specific narrative publications, this study examines the ability of learning methods to build predictive models for mCRC patients, either for chemotherapy alone or combined with targeted therapy. The results show promising outcomes in predicting treatment response or toxic side-effects. Radiomics and molecular biomarkers are able to accurately identify responders and non-responders in the majority of patients.
Article
Biochemistry & Molecular Biology
Patrizia Ferroni, Raffaele Palmirotta, Gabriella Egeo, Cinzia Aurilia, Maria Giovanna Valente, Antonella Spila, Alberto Pierallini, Piero Barbanti, Fiorella Guadagni
Summary: The study investigates the association between white matter hyperintensities (WMHs) and genetic pro-inflammatory/pro-oxidative status in migraine patients. The results show no significant difference in gene polymorphisms between patients and controls. However, specific alleles of the lymphotoxin alpha (LTA) and superoxide dismutase 1 (SOD1) genes are associated with WMHs. This suggests that an imbalance between pro-inflammatory/pro-oxidative and antioxidant events may contribute to the development of WMHs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)